摘要
目的探讨伊达比星在自体造血干细胞移植治疗急性淋巴白血病预处理方案中的作用。方法回顾性分析我科2008～2012年进行自体造血干细胞移植的14例急性淋巴细胞白血病患者,观察不同预方案后患者造血重建、移植相关并发症和长期随访情况。结果所有患者均造血重建。含有伊达比星组复发率28.5%,无病生存率57.1%,总体生存率为85.71%;未含有伊达比星组复发率57.1%,无病生存率为42.8%,总体生存率为71.43%。结论伊达比星作为预处理方案的自体造血干细胞移植术治疗急性淋巴细胞白血病安全有效。
Objective To explore the roles of idarubicin in the conditioning regimen for patients with acute lympho- cytic leukemia undergoing autologous hematopoietic stem cell transplantation. Methods We retrospectively analyzed hematopoietie reconstitution, complication and survival analysis for 14 patients with acute lymphocytic leukemia undergo- ing autologous hematopoietic stem cell transplantation from 2008 to 2012. Results All patients were hematopoietic re- constitution. The rate of the disease recurrence for patients with idarubicin in the conditioning regimen was 28. 5 %, Dis- ease free survival and overall survival rate was 57.1~ and 85.71%, respectively. The rate of the disease recurrence for patients without idarubicin in the conditioning regimen was 57.1%, Disease free survival and overall survival rate was 42.8% and 71.43%, respectively. Conclusion Idarubicin as a conditioning regimen in the treatment of acute lympho- blastie leukemia with autologous hematopoietic stem cell transplantation is safe and effective.
出处
《西部医学》
2012年第11期2070-2071,共2页
Medical Journal of West China
基金
重庆市医学重点学科(编号:2006C028)
第三军医大学新桥医院"1130"人才工程培养基金资助(编号:2012)
